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Inflammation is the normal biological response to tissue injury, and is characterised by the 
interactive activation of multiple mediators and cell types. One response to tissue injury is 
the production of pain, not only by direct trauma to sensory fibres, but also through the 
release of mediators from sensory nerve terminals. One such mediator is kinin which is a 
vasoactive peptide considered to play a primary role in inflammation by causing 
constriction of venules, dilation of arterioles, increasing permeability of the capillary 
membrane, and interacting with sensory nerve terminal transmitters to evoke pain. The kinin 
forming enzymes (kallikreins) reach inflammation sites either on the surface of migrating 
neutrophils or by transudation from plasma. The kininogen molecule which contains the 
kinin moiety, has been localised on the external surface of the neutrophil, and provides the 
substrate from which kinins can be cleaved through enzymatic action. The cellular actions 
of kinins are mediated through B2 receptors, which are also located on the external surface 
of the neutrophils . In addition, the induced effects of kinins are regulated by Bl receptors. 
The formation of nitric oxide (NO) from arginine released from the kinin C terminus, and 
receptor membrane signal transduction by nitric oxide following kinin receptor activation 
is discussed. 
A molecular response to cell injury is the formation of chemotactic mediators that attract 
neutrophils to sites of inflammation. The question whether neutrophils contribute to 
circulating levels of kinins was examined in infections and inflammatory disorders . This 
novel hypothesis was tested using circulating neutrophils harvested from patients with 
tuberculosis meningitis and pneumonia. These neutrophils showed a distinct loss of only 
the kinin moiety from the kininogen molecule located on the external surface. The confocal 
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images of fixed, permeabilised neutrophils provided multi-dimensional constructs, and the 
intensity of fluorescence reflected the relative amounts of the molecule present in both 
neutrophils harvested from healthy volunteers as well as patient blood. The 
immunocytochemical labelling experiments using colloidal gold as markers, confirmed, at 
the ultrastructural level, the presence or disappearance of the kinin moiety from the 
kininogen molecule on the neutrophil surface. 
The cell component of synovial fluid in rheumatoid athritis (RA) consists mainly of 
neutrophils . This study demonstrates the absence of the kinin moiety from circulating and 
synovial fluid neutrophils from patients with RA, as well as an increased signal from 
immunolabelled B2 receptors in synovial fluid neutrophils. These findings support the 
hypothesis that in RA, kinins are released during the inflammatory response in the joints, 
and suggests that there is an upregulation of the B2 receptor at the site of inflammation. 
Neutrophils chemotactically drawn to the site of inflammation become activated to release 
kinin from the kininogen molecule, and thereafter re-enter the circulation where they were 
harvested systemically. B2 receptors may be upregulated following activation by kinins or 
by other mediators present in the inflammatory milieu. Interleukin-l has been shown to 
upregulate kinin receptors on human synovial cells. 
Anti-peptide antibodies to the loops of cloned Br and B2 receptors have provided powerful 
probes for the cellular identification of the two kinin receptor families. Mapping of the B2 
receptors showed upregulation on the neutrophils gathered from inflamed joints. However, 
no activation of the Br receptors was observed in normal blood neutrophils as well as those 
obtained from the different disease states. 
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1.1 Historical Overview 
Advances in biochemistry and molecular biology in recent years have established the 
chemical structure and molecular sequences of the various components of the kallikrein-
kinin system. The essential significance of the kallikrein-kinin system is of widespread 
interest to the cellular basis of medicine, in particular, many inflammatory disorders , 
Initial observations of the protein later called kallikrein were made by the surgeon, E.K. 
Frey in 1926 when he injected human urine into dogs, and observed a hypotensive response 
(Frey and Kraut, 1928). He attributed this effect to a substance that he considered to be 
a hormone. This substance was later called kallikrein - derived from the Greek synonym 
for pancreas, where it was present in high concentrations (Kraut et aI. , 1930), and therefore 
thought to be its place of origin (Bhoola et aI., 1992). The substance protein kallikrein, 
responsible for the observed hypotensive effect was isolated and subsequently shown to be 
a non-dialysable, thermolabile substance of high molecular weight (Frey and Kraut, 1928). 
These observations were followed by many publications by the German biochemist, Eugen 
Werle, and co-workers (Werle et aI. , 1937) who demonstrated that kallikrein was present 
in blood, pancreas and salivary glands (Frey and Kraut, 1928). Werle, in 1948, further went 
on to study the biochemical properties of kallikrein, and subsequently discovered that 
kallikrein was a proteolytic enzyme which released a smooth muscle-contacting substance 
from an inactive precursor (kininogen). Further, it was observed that the new activity 
increased and then rapidly disappeared. The new, biologically active molecule was called 
kallidin (Werle and Berek, 1948) and, unlike kallikrein, it was dialysable and thermostable, 
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contracted the isolated guinea-pig ileum and showed marked hypotensive activity CW erle 
and Grunz, 1939). Both kallikrein and kallidin showed different responses in inhibition 
studies; aprotinin inhibited kallikrein but not kallidin. Furthermore, kallidin was irreversibly 
inactivated by proteases in plasma and tissue extracts, and this inactivation was initially 
attributed to degradation by peptidases called kininases. Hence, in 1948, kallidin was the 
first of the "kininsll to be named as such. 
About this time, in 1949, Brazilian pharmacologists, Beraldo, Roche e Silva and Rosenfeld 
discovered a kinin (Roche e Silva et aI. , 1949), which was also released from plasma 
proteins by trypsin and snake venom proteases. They called this new kinin, bradykinin, 
because it produced a slow contraction of the isolated guinea-pig ileum. Later, Werle et al. 
(1950) showed that both kallidin and bradykinin were released from the same precursor 
proteins, later called the high and low molecular weight kininogens (Fritz et aI., 1988). 
Pharmacologically active peptides similar to kallidin and bradykinin have since been 
discovered in insect venoms (Schachter et aI. , 1978). In 1960, Bhoola et al. discovered the 
presence of a kinin-like peptide in the venom of hornets, and this venom also contained 
high concentrations of acetylcholine and histamine. Over the years an in depth 
understanding of the kallikrein-kinin system has been acquired especially knowledge of the 
two different kallikrein-kinin systems, plasma and tissue. 
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1.2 Turnover of kinins 
1.2.1 Kallikreins 
The kallikreins are a group of serine proteases that are found in glandular cells, neutrophils 
and biological fluids (Bhoola et aI., 1979). On the basis of their molecular weight, 
isoelectric points, substrate specificity, immunological characteristics and type of kinin 
released, the kallikreins are designated into plasma and tissue kallikreins . 
1.2.1.1 Tissue kallikrein (TK) 
Although tissue kallikrein was previously discovered in the pancreas, salivary glands and 
kidney by Werle and his colleagues (Frey and Kraut, 1928), it was only recently discovered 
in the neutrophil (Bhoola et aI. , 1992). Initial characterisation of TK was achieved in the 
porcine (Fritz et aI. , 1967), rodent and canine pancreas (Hojima et aI., 1975). However, 
early purification of the enzyme was carried out from the salivary glands of the rat 
(Brandzaeg et aI. , 1976), cat (Moriwaki et aI. , 1975), pig (Lemon et aI. , 1979), mouse 
(Porcelli et aI., 1976) and guinea pig (Fiedler et aI., 1983). The discovery, isolation and 
purification of this enzyme in the various tissues has enabled an extensive study of the 
biochemical, immunological and enzymatic properties of tissue kallikrein. 
TK was localised in the granules, tubules and striated duct cells of submaxillary glands 
(Hojima et aI. , 1975; Orstavik et aI., 1976), in the rat transplantable acinar cell carcinoma 
of the pancreas (Berg et aI. , 1985), in the connecting tubule cells of the kidney (Tomita et 
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aI., 1981), in the colonic mucous cells (Schachter et aI., 1983), in the epithelial cells lining 
the lumen of the coagulating gland and prostate (Schachter et aI., 1978), in the glands of 
the trachea (Bhoola et aI., 1989) and nasal mucosa (Baumgarten, et aI., 1989), ependymal 
cells lining the third ventricle and cell bodies of the arcuate, supraoptic, paraventricular and 
ventromedial nuclei of the brain (Simson et aI., 1985), prolactin secreting c~lls of the 
anterior pituary (Vio et aI., 1990), and human circulating (Figuerao et aI., 1990) and 
synovial fluid neutrophils (Rahman et aI. , 1994). Recent immunocytochemical and in situ 
hybridisation studies in this laboratory should advance knowledge with regard to the storage 
and synthesis sites of tissue kallikrein. 
TK is an acidic glycoprotein with molecular weight, depending on the site of origin, 
ranging from 30 to 45 kDa, and the isoelectric point ranging from 3.5 to 4.4. The enzyme 
from the different tissues is similar in enzymatic, immunological and chemical properties. 
Similar to other serine proteases of the trypsin, chymotrypsin and elastase group, the serine 
residue in TK forms a triad with histidine and aspartic acid, and this spatial arrangement 
forms the catalytic triad necessary for its enzymic activity. Glycosylation sites vary in 
number and position in different species and cells in which the enzyme is synthesised. One 
mole of kallikrein has one glycosylation site in the rat and mouse, whereas porcine 
pancreatic kallikrein has 2 or 3 sites (Fritz et aI., 1967), and human urinary kallikrein has 
3-asparagine linked sites (Lu et aI., 1989) and 3 additional oxygen glycosylation sites linked 
to 2 serine and 1 threonine residues (Kellerman et aI., 1988). Human urinary kallikrein is 
comprised of 238 amino acid residues with isoleucine at the amino terminus and serine at 
the carboxyl terminus (Geiger et aI., 1979), and the carbohydrate moieties contain fucose, 
mannose, galactose, N-acetylglycosamine and sialic acid (Moriya et aI., 1983). In addition, 
5 
sialic acid seems to partially influence the thermal stability of TK because asialic forms 
of the enzyme are less stable than the intact molecule. 
TK is synthesised bound to a signal peptide of 17 ammo acids, that is cleaved off to 
produce an inactive precursor. In addition to the active enzyme, the inactive pro-form is 
found in varying amounts in most tissue and body fluids. This pro-enzyme can be activated 
in vitro by proteolytic enzymes like trypsin (Kamada et aI., 1988). This activation can also 
be achieved by thermolysin, a bacterial metalloprotease. The cleavage site for the 
conversion to the active form is between Arg-7 and Ile-8. Thermolysin is four times more 
effective than trypsin in activating the human urinary pro enzyme (Noda et ai. , 1985). The 
amino terminus of the pro-enzyme is alanine, and after removal of a seven amino acid 
peptide, isoleucine forms the new N-terminus (Takada et aI., 1985) (fig 1). Since the 
sequence of the activation peptide is -Ala-Pro-Pro-Ile-Gln-Ser-Arg- (Girolami et aI., 1986), 
the pro enzyme can be activated in vitro by either trypsin or thermolysin which hydrolyses 
the Arg-Ile bond. The endogenous enzyme that performs this function physiologically has 
not been identified, as yet. TK is a well characterised component of saliva (Sakamoto et aI. , 
1980; Gieger et aI., 1983) and it has been suggested that the salivary protein is either 
identical or closely related to the TK found in urine and other biological fluids. Jenzano et 
aI. (1992) showed that there is considerable variation in TK expression in salivary gland 
secretions. They demonstrated the presence of a tissue prokallikrein in human mixed saliva 
~, .. : 
indicating the possibiltiy of at least two immunoreactive forms of TK in saliva, mature TK 




Figure 1: Amino acid sequence of prokallikrein showing amino termini of prokallikrein 
andTK. 
Peptide CAP-II represents prokallikrein and is derived from the first letter 6 
the first three amino acid residues of the amino terminal of prokallikrein. 
TK forms kallidin (Lys-bradykinin) from the preferred substrate low molecular weight 
kininogen, but in vitro TK is considered to release kinins from both low (LK) and high 
molecular weight (HK) kininogens (Iwanaga et aI. , 1977). The process of forming kallidin 
by TK involves the cleavage of a Met-Lys bond at the N-terminus in the kinin sequence 
of the kininogen molecule (Pisano et aI., 1974). TK of most mammalian species is unable 
to form bradykinin because of its inability to accommodate the Lys-Arg-Pro sequence for 
hydrolysis of the Lys-Arg bond on the amino terminus of the peptide. 
Human kallistatin is a newly discovered protein, and is a tissue kallikrein inhibitor. Chao 
and Chao (1995) purified and cloned human, rat and mouse kallikrein binding proteins. The 
reactive site of kallistatin has a unique sequence at P2-P CPI of Phe-Phe-Ser. Site directed 
mutagenesis was carried out to determine the structural and functional properties of 
kallistatin. Chao et aI. (1995) showed that PI Phe is a crucial specificity determinant, and 
P 2 Phe is important for the hydrophobic environment of the kallikrein-kallistatin interaction. 
PlO and P 12 Phe residues are important for maintaining kallistatin conformation. Enzyme 
linked immunosorbent assays (ELISAs) and in situ hybridisation studies have shown that 
there is a wide distribution of kallistatin in blood cells, body fluids and tissues of healthy 
and diseased individuals. Plasma kallistatin levels are altered in patients with liver disease, 
sepsis and pre-eclampsia. The expression of kallistatin in the rat is downregulated during 
acute phase inflammation, and is upregulated by sex hormones. Chao et al. (1995) found 
that kallistatin levels were reduced in genetically hypertensive rats, and in the arterial 
hypertensive rat model induced by the inhibition of nitric oxide synthesis. 
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Today, techniques determining concentration for TK in tissue extracts and in biological 
fluids are diverse. Methods include kininogen as the substrate, in which kinin is released 
and the free kinin estimated by bioassay (Bhoola et al., 1962), radioimmunoassay (Miwa 
et al. , 1968) or enzyme linked immunosorbent assay (ELISA) (Geiger et al., 1986), and 
high pressure liquid chromatography (Kato et al., 1985). Another method is the hydrolysis 
of the selective, synthetic substrates (Lu et al., 1989) by which the activity of TK may be 
determined, and the parent molecule identified using a mono clonal antibody (Takahashi et 
al., 1988). In addition, antibodies to TK can be used to specifically inhibit the enzymic 
activity of TK. In order to predict the amount of pro enzyme in a sample, synthetic substrate 
assays are performed before and after trypsin or thermolysin activation and, in this way, 
values for both active and inactive components can be determined. 
Using these techniques, it has recently been established that circulating neutrophils contain 
a TK (Bhoola et al., 1992). TK in circulation could be affected by degranulating 
neutrophils . It has been suggested that in vivo, the liver is the main organ that clears TK 
from circulation. Although the accepted property of TK is to form kallidin, other enzymic 
functions have been attributed to TK, and these include conversion of inert, precursors of 
enzymes and hormones into biologically active molecules (Bhoola and Dorey, 1971; 
Bothwell et al., 1979; Mason et al. , 1983). The finding of immunoreactive TK in the cells 
of pancreatic islets (Pinkus et al., 1983), and in the lactotroph cells of the rat (Vio et al., 
1990) and human anterior pituitary (Noda et al., 1985) suggests that the functional role of 
this enzyme may be specific to cell types. 
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1.2.1.2 Plasma kallikrein (PK) 
Plasma kallikrein occurs in zymogen form, and differs from TK III its biochemical, 
immunological and functional characteristics. PK is synthesised as a zymogen III 
hepatocytes, secreted into the bloodstream where it circulates as a heterodimer complex 
bound to its substrate, high molecular weight kininogen (HK). The PK-HK complex, and 
Hageman factor (HF) are involved in the activation of the complement system. Further, the 
complex plays an important role in the surface-dependent activation of HF that results in 
coagulation of blood, formation of kinins, regulation of vascular tone and fibrinolysis . The 
pro enzymes involved in clotting include Factor XII (HF), Factor XI (plasma thromboplastin 
antecedent) and plasma prekallikrein (Fletcher factor). Once the cascade is triggered, 
clotting occurs to initiate thrombus formation together with the formation of active PK and 
the release of kinins on endothelial and subendothelial surfaces. The clotting cascade is 
initiated by the conversion of inactive Factor XII into a two chain active HFa by either 
exposure to macromolecular anionic surfaces or by enzymatic action of PK (Cochrane et 
aI. , 1973). Active HFa comprises a heavy chain of 50 kDa, which has the binding site for 
the attachment to anionic surfaces during activation, and a light chain of 28 kDa linked 
together by a disulfide bond (Revak et aI. , 1978; Revak et aI., 1977). The light chain has 
the active site (Revak et aI. , 1976; Kaplan and Silverberg, 1987) for converting the plasma 
prekallikrein (PPK) zymogen into an active form (Miller et aI. , 1980; Silver et aI. , 1980; 
Siverberg et aI., 1980). The cascade progresses rapidly as soon as a sufficient amount of 
PK is formed. PK forms more HFa and drives the reaction forward to activate Factor XI , 
that enhances clotting, and plasminogen that initiates fibrinolysis. With rising levels, PK 
enzymatically cleaves HK from which bradykinin is released. 
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A single gene codes for PPK which is synthesised in liver hepatocytes and secreted as an 
inactive molecule. HK is also synthesised in the liver and when both HK and PK are 
secreted into the circulation, they form a complex with Factor XI of the intrinsic clotting 
system. This complex circulates bound to the outer surface of the human neutrophil (Naidoo 
et ai. , 1994a). PPK exists as a single chain glycoprotein with an isoelectric point of 8.9. The 
enzyme exists in two forms of 85 and 88 kDa and both forms are present in plasma 
(Talama et ai. , 1969). The mature human enzyme is made up of 619 residues with 371 
residues at the amino terminus linked to a catalytic chain of 248 residues. HK is the 
prefered substrate for PK which releases bradykinin from it by hydrolysis of Lys-Arg and 
Arg-Ser bonds to yield the nonapeptide with Arg at both amino and carboxy terminals. 
In spite of the fact that LK is a poor substrate, PK does form bradykinin from LK in the 
presence of neutrophil elastase. This is possible because neutrophil elastase cleaves a 
fragment from LK from which PK readily releases bradykinin (Kitamura et ai., 1985). It 
is possible that this reaction occurs in vivo for kinin generation from low molecular weight 
kininogen, and this activity has important implications because LK has been localised on 
the external membrane of the neutrophil. PK has a significant effect on PMN leucocytes, 
and therefore, is considered to play an important role in inflammation (Henderson et ai. , 
1994). 
1.2.2 Kininogens 
The endogenous protein substrates for TK and PK are kininogens, which by proteolytic 
cleavage form the vasoactive peptides - kinins. Cysteine proteinase inhibitor domains also 
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exist in kininogen molecules, and may therefore act as cofactors for inhibition of lysosomal 
enzymes released during inflammation. Hepatocytes play a role in the synthesis and release 
ofkininogens into circulation (Kitamura et aI. , 1985; Muller-Esterl., 1988). Current studies 
have shown that HK and LK are not restricted to extracellular fluids, but also occur in 
several cell types. Kininogens have so far been identified in the collecting ducts of the 
human kidney (Proud et aI. , 1891 ; Figueroa et aI. , 1988), platelets (Schmaier et aI., 1983; 
Schmaier et aI. , 1986), sweat glands (Poblete et aI. , 1994), endothelial cells (Schmaier et 
aI. , 1988) and human neutrophils (Gustafson et aI. , 1989). Figueroa et al. (1990) identified 
HK on the external surface of human neutrophils, and described for the first time the 
presence of LK on these cells. In contrast, it was observed that when platelets were 
activated, HK was translocated from the granules to the external surface of the cell 
membrane, where the binding of HK to the membrane probably involves specific acceptor 
proteins exposed on the outer surface of cells. Binding sites for HK which are specific, 
saturable and reversible have been identified on the cell membranes of platelets (Greengard 
and Griffin, 1984; Gustafson et aI., 1986; Meloni and Schmaier, 1991), cultured human 
endothelial cells (Gustafson et aI., 1986; van Iwaarden et aI., 1988) and neutrophils 
(Gustafson et aI. , 1989). 
The kininogens are single-chain glycoproteins that possess the kinin moiety interleafed 
between the two polypeptides that are bridged by single disulfide loops (Kellerman et aI. , 
1987). The two kininogens differ with respect to structure, size and enzymatic susceptibility. 
HK is composed of 626 residues and, depending on the species of origin, has a molecular 
mass of 88 to 120 kDa (Kerbiriou et aI. , 1980; Jacobsen et aI., 1966; Komiya et aI. , 1974). 
LK consists of 409 residues and varies from 50 to 68 kDa in size (Kato et aI. , 1976; 
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Muller-Esterl et aI., 1985). The molecular architecture of these proteins has been analysed 
by limited proteolysis. The kininogen molecule consists of multiple domains; HK has 6 
domains (D1 - D6) and LK has 5 domains (D1 -D5) (Muller-Esterl et ai., 1986; Kato et ai., 
1981) (fig 2). 
The heavy chain basic structure of the two kininogens is the same, and forms the 3 amino 
terminal domains that make up 50-60 kDa. The fourth domain contains the kinin segment 
followed by a light chain, that varies in the two kininogen molecules (Kellerman et ai., 
1986; Lottspeich et ai., 1985). For HK, the light chain has two segments and a molecular 
weight of 45 to 58 kDa. In LK the light chain is smaller and single with a sequence of Met-
Lys-bradykinin at its amino terminus (Kato et ai., 1985). Cysteine proteinases, such as 
cathepsin B, papain and platelet calpain, are inhibited by domains 2 and 3 of the heavy 
chain (Ohkubo et ai., 1984; Muller-Esterl et ai., 1985; Schmaier et ai., 1986). The histidine 
rich region of domain 5 in the light chain of HK it anchors onto anionic surfaces during 
initiation of the intrinsic clotting cascade. Domain 6 provides a binding site for PPK and 
the clotting factor XI. Since PPK is coupled to domain 6 of HK, conversion of PPK to 
active kallikrein on the neutrophil membrane may bring about the release of the kinin 




Colman (1995) probed the kininogen molecule with mono clonal antibodies, peptides and 
deletion mutagenesis to elucidate its interaction with other proteins, surfaces and cells. He 
found that domain 2 inhibits platelet calpain while domain 3 has the ability to block 
thrombin-induced activation of platelets. Domain 3 also contains a binding site for 
neutrophils, and this, he postulated, may modulate neutrophil adhesion to artificial surfaces. 
Domain 5 of HK was found to contain 2 regions which reacted with negatively charged 
surfaces and cells, one of which interacted with neutrophils and endothelial cells. Domain 
6 plays an important role in the cofactor function of kininogen, as this site houses FXII and 
prekallikrein, the latter of which upon activation causes the liberation of bradykinin from 
domain 4. In order to determine how kininogens place themselves in their binding sites on 
endothelial cells, Schmaier et al. (1995) sought to determine the sequences on kininogen 
that participate in endothelial cell binding and found that domains 3, 4 and 5 all contain 
binding sites. 
1.2.3 Metabolism and cellular actions of kinins 
Kinins are vasoactive peptide mediators that are formed immediately after a primary injury 
event. Therefore, they are an important target for therapeutic intervention. Kinins are 
capable of producing all of the observed cellular effects in inflamed tissues. These include 
vasodilation, venoconstriction, pain and endothelial cell retraction that result in vascular 
leakage. Kinins are capable of releasing transmitters such as substance P from nerve 
terminals, stimulating the synthesis of cytokines such as interleukin 1 (IL-l) and tumour 
necrosis factor (TNF), inducing the formation of prostaglandins and leukotrienes by 
activating phospholipase A2 and releasing endothelium-derived relaxing factor (EDRF; nitric 
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oxide) from endothelial cells. Injected intravenously, kinins produce a rapid drop in blood 
pressure with a gradual return to baseline over a period of several minutes . With very high 
doses, pulmonary and systemic vascular leakage occurs, resulting in cyanosis and oedema. 
Injection of bradykinin into the carotid artery results in pseudoaffective responses and 
vocalisation, suggesting severe pain (Ricciopo et aI. , 1974). It is generally accepted that 
kallidin (Wede et aI. , 1961) is formed from LK by TK, and bradykinin from HK by the 
action of PK (fig 3). Bradykinin is a nonapeptide of 1060 daltons and kallidin is a 
decapeptide of 1188 daltons . 
The conversion of kallidin (Lys-bradykinin) to bradykinin may occur in the circulation and 
tissue fluids through removal of the amino terminal lysine by aminopeptidases (Rodell et 
aI. , 1995). Once produced, bradykinin and kallidin are inactivated by several different 
kininases, therefore the effects of kinins in biological fluids are often very short-lived 
because they are rapidly destroyed by potent peptidases (fig 4). Circulating 
carboxypeptidase N and the membrane bound carboxypeptidase M (kininase I) cleave the 
C-terminal Arg of bradykinin to produce des-Arg9-bradykinin. Angiotensin converting 
enzyme or kininase 11 cleaves 2 internal bonds, producing completely inactive metabolites. 
Aminopeptidases (prolidase) remove the N-terminal Arg. In addition, a neutral 
endopeptidase that occurs on the surface of endothelial cells, and the outer surface of the 
neutrophil membrane also degrades the molecule. 
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Figure 3: Cleavage sites for TK and PK on the kininogen molecule 

In blood, the reported half life of about 30 sec for bradykinin and kallidin requires to be 
confirmed (McCarthy et aI. , 1965). Kinins in biological fluids and tissue homogenates are 
mostly readily measured by radioimmunoassay. The finding of varying tissue levels may 
be due to the fact that the kininogenases and kininases may not have been adequately 
inhibited, and a difference in the type of antibody used. More recently, a mean value of 3.8 
pg/ml was recorded when syringes containing 0.8 M hydrochloric acid (HCI) were used to 
withdraw blood samples. Kinins in the urine amount to 24.6 Jlg/day in samples collected 
in HCI and pepstatin containing flasks (Scicli et aI., 1982). Kinin levels have also been 
reported in nasal fluids (Shimamoto et aI., 1982), bronchoalveolar lavage fluid (Christianson 
et aI. , 1987), human (Scicli et aI., 1984) and rat CSF (Hermann et aI., 1986) and synovial 
fluid from patients with rheumatoid and osteoarthritis (Rahman et aI., 1994). 
1.2.4 Kinin receptors and signal transduction 
The cellular effects of kinins are mediated by two different classes of receptors, namely Bl 
and B2 . Studies of the structure and activity of these receptors have been carried out to 
determine the potency of agonists, differences in activity profile, affinity of competitive 
antagonists and mechanisms involved in signal transduction. The Bl (Hess et aI., 1994) and 
the B2 (McEachern et ai. , 1991) receptors have been cloned and have been found to belong 
to the superfamily of G-protein receptors. These receptors have the characteristic of seven 
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transmembrane spaning regions comprising three extracellular and four intracellular loops, 
that are unique in their sequences (Hess et aI., 1994). The B2 receptor seems to be the 
physiological receptor, instrumental in most of the reported actions of kinins . The Bl 
receptor has attracted interest because of its apparent upregulation following induction of 
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inflammation (Marceau et aI. , 1995). 
In addition to the Bl and B2 receptors, Farmer et aI. (1991) proposed an airway B-subtype 
receptor in the trachea of guinea pigs; however, its significance in humans is still unknown. 
Both isolated cell membrane fragments and intact cultured cells have been used to 
demonstrate the bradykinin receptor coupling to second messenger systems. Although 
bradykinin increases free cytosolic calcium in many tissues, in vascular smooth muscle, the 
intracellular calcium is mobilised by receptor coupled activation of phospholipase C, 
hydrolysis of inositol biphosphate and formation of inositol triphosphate. The coupling of 
kinin receptors to secondary messenger systems is through a family of G proteins. The 
particular second messenger system initiated, therefore, may be a function of the receptor-
coupled G protein in each cell type, indicating the occurence of B2 receptor subtypes. 
Two B2 bradykinin receptor subtypes have been described: a smooth muscle and a neuronal 
B2 receptor which differ pharmacologically. The B2 smooth muscle receptor has been cloned 
from several species, whereas this is the first report of cloning the neuronal B2 receptor. 
The B2 receptor was proposed as an important gene involved in the manifestations of 
common chronic disorders such as hypertension and ischaemic heart disease, since 
bradykinin has been implicated in a variety of physiological and pathological processes. 
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1.3 Role of Nitric Oxide (NO), the second messenger, in sepsis and infections 
Neutrophil accumulation in tissue is a characteristic of inflammation, and is associated with 
a variety of pathological conditions (Spitzer et al., 1994). Bacterial infections are 
characterised by the selective aggregation of neutrophils in large numbers to phagocytose 
and kill invading micro-organisms. However, activated neutrophils can also cause injury to 
tissues. There is a growing body of evidence to suggest that NO regulates neutrophil-
endothelial cell interactions, which is a key feature of inflammation and may, therefore, 
modulate the inflammatory response (Kubes, 1995). It has been postulated that inhibition 
of NO synthase, the enzyme forming NO through the conversion of L-arginine to L-
citrulline, promotes neutrophil adhesion. 
Septic shock is the host' s inflammatory response to infection. The pathogenesis of septic 
shock is mediated by a variety of endogenous substances. Some of the major mediators 
include cytokines, NO and prostaglandins (Castillo and Sanchez, 1993). Management of 
septic shock is focussed on maintaining haemodynamic stability and an adequate oxygen 
delivery and utilization. The most important factor to prevent complications and improve 
outcome is to give careful attention to each organ-system. Endotoxin and other bacterial 
products induce the release of mediators which alter the circulation and cellular metabolism 
and one such mediator is NO (Rosenberg et aI., 1994). The proposed mechanism by which 
NO initiates intracellular events is the activation of guanylate cyclase with subsequent 
biosynthesis of 3'5' cyclic guanosine monophosphate. Tiao et al. (1994) observed that NO 
production increases during sepsis and endotoxaemia. Inhibition of NO synthetase has been 
suggested as a therapeutic modality in sepsis and endotoxemia, but in recent reports NO 
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synthase inhibition increased mortality rate. However, the mechanism of this phenomenon 
is not known. The detrimental effect of NO synthase inhibition during endotoxemia may 
be caused by excessive production of tumour necrosis factor (TNF) and interleukin-6 (IL-6). 
1.4 Neutrophils and the kallikrein-kinin system . 
Normal human blood consists of leucocytes of different morphology, and classification is 
based on the presence or absence of granules staining with acridine dyes in the cytoplasm, 
as well as the shape of the nucleus. Neutrophils, eosinophils and basophils are the granular 
leucocytes (polymorphonuclear), and are classified according to specific staining affinities 
of the intracellular granules. The non-granular leucocytes are divided into monocytes and 
lymphocytes. Neutrophils, as with all granulocytes, originate from stem cells located in the 
bone marrow, and the stem cells in turn originate from pluripotential stem cells which are 
referred to as the colony forming units. The pluripotent cells self-replicate into progenitor 
stem cells, one of which becomes committed to the formation of granulocytes. Maturation 
of the neutrophil from the stem cells takes about 10 days, after which the neutrophil 
remains in the bone marrow for 5 days before going into the circulation, extracellular tissue 
space and biological fluids . 
During immunocytochemical studies on a pyelonephrotic human kidney (Figueroa et aI. , 
1989), it was observed that there was an infiltration of neutrophils, in which TK was 
discovered as shown by an intense granular pattern of immunostaining. Figueroa et al. 
(I989) examined, and identified, immunoreactive tissue kallikrein in polymorphonuclear 
(PMN) leucocytes of normal human blood and bone marrow, specifically in the mature 
22 
neutrophils as well as in immature forms such as metamyelocytes and myelocytes. Further, 
no tissue kallikrein was detected in eosinophils, lymphocytes, macrophages, megakaryocytes 
and platelets. Additionally, large numbers of neutrophils were observed in the synovial 
fluid and membranes of patients with rheumatoid arthritis . It is therefore likely that TK 
from the neutrophils could form kallidin in an inflamed joint. This finding was important 
since a major role has been postulated for TK in acute inflammation, in which granulocytes 
are considered to participate in regulating vascular permeability by contributing kinins. 
Although immunoreactive TK was localised subcellularly in the granules of the neutrophils, 
it has not been determined whether the enzyme is contained in azurophilic or specific 
granules. 
If TK is indeed synthesised in the neutrophil, its expression would be controlled by a single 
gene that encodes a pre-pro-enzyme with a 17 amino acid signal peptide, that is 
subsequently split off during protein translocation within the cells. Anders et al. (1994) 
demonstrated for the first time that tissue prokallikrein speciftcally binds to intact human 
neutrophils and structural features of the zymogen are required for the interaction with 
unoccupied sites on the neutrophil surface. The question of whether TK is synthesised in 
situ or emniocytosed after binding to its membrane receptor has yet not been answered 
unequivocally. 
Changes in vascular calibre and tone, as well as an increase in vascular permeability leading 
to the formation of a protein rich exudate, are all part of the acute inflammatory response. 
Neutrophils participate actively in such a response, initially within vessels where they 
marginate and adhere to the vascular endothelial cells, and later when they migrate through 
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the vessel wall to reach the site of inflammation or injury. Macrophages and lymphocytes 
follow later after the ftrst arrival of the neutrophils which is usually within a few minutes. 
During the early stages of inflammation, bradykinin, produced by the action of PK on HK, 
may be an important mediator of changes in vascular permeability or calibre. This property 
has led to the conclusion that kinins are likely to be formed also in the protein rich exudate 
present in acutely inflamed areas. Recently, researchers have suggested that during acute 
inflammatory reactions, locally generated chemotactic factors attract neutrophils to vessel 
walls, where they play a role in the control of vascular tone and capillary permeability, 
leading to the protein and fluid exudation (Issekutz, 1984), prior to migrating to the site of 
inflammation. 
SpecifIc, reversible, and saturable binding sites for HK have been previously determined 
in human neutrophils by Gustafson et al. (1989). Experiments with platelets have shown 
that when theses are activated, HK is translocated form the alpha granules to the external 
surface of the cell membrane. Figueroa et al. (1992) showed that, in the neutrophil, 
immunoreactivity for HK and LK was restricted to the cell membrane, and that it was 
absent from granules and other organelles. They concluded that clusters of kininogen 
molecules present on the neutrophil surface represented kininogen bound to speciftc 
receptor proteins. Both the kininogens associated with the neutrophil membrane were 
thought to have originated from the plasma pool although they could be synthesised in the 
neutrophil and translocated to the cell membrane. With the availability of speciftc 




Neutrophils contribute to circulating levels of kinin in infections and inflammatory 
disorders. 
1.6 Aims 
The aim of the current study was to demonstrate immunocytochemically, the presence 
or absence of the different components of the kallikrein-kinin system, and kinin 
receptors on the human neutrophil in blood from normal, healthy volunteers as well 
as blood from patients with sepsis and clinical disorders. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Neutrophil isolation 
2.1.1 Reagent 
Phosphate buffered saline pH 7.2 (PBS) 
NaH
2
P04.2H20 (3.12 g), Na2HP04.H20 (11.32 g), NaCl (8.5 g) were dissolved in 950 ml 
distilled H20, titrated to pH 7.2 with NaOH, and made up to 1 litre. 
2.1.2 Procedure 
Whole blood (10 ml) was obtained by venipuncture through a precision glide vacutainer 
needle (Becton Dickinson Vacutainer Systems, UK) from healthy volunteers and patients 
presenting with pneumonia, myeloid leukaemia and rheumatoid arthritis at King Edward 
VIII Hospital, and patients presenting with tuberculosis meningitis at Wentworth Hospital, 
Durban, Natal. Blood samples were obtained from patients with informed consent. Each 3 
ml was drawn into a vacutest tube (Radem Medical, Sandton, SA) containing 0.5 ml of 
3.8% (w/v) sodium citrate. The anticoagulated blood was pooled and mixed with an equal 
volume of phosphate buffered saline (PBS). Neutrophils were isolated by careful layering 
of blood (7 ml) on 3.5 ml Histopaque 1119/1 077 (Sigma, UK), and on centrifugation (1 5 
000 x g, 30 min, 200e) neutrophils formed a band. Neutrophils from this layer were 
harvested with a pasteur pipette, mixed with an equal volume of PBS, centrifuged, and the 
washing process repeated twice. 
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Therapeutically aspirated synovial fluid obtained from patients with informed consent was 
centrifuged (10 000 x g, 7 min, room temperature) to remove cells and debris and the 
supernatants were thoroughly mixed, dehydrated through a graded series of alcohol (70%, 
90% and 100%) and wax embedded. Three micron sections were then cut on a Leica Jung 




Paraformaldehyde (2 g) was added to 80 ml distilled H20, heated to clear with 5 drops 
NaCl (1 M) and made up to 100 m!. 
Blocking solution (1% Bovine serum albumin and 1% human rgG in PBS) 
Bovine serum albumin (BSA) (0.01 g) and human rgG (10 Ill) was dissolved in 1 ml PBS. 
Kaiser's jelly mounting medium 
Gelatin (10 g) was added to 60 ml distilled H20 and heated to dissolve the gelatin after 
which 70 ml of glycerol and 0.25 g of phenol were added. Jelly was heated before use. 
Toludine blue 
Toludine blue (2%) (5 ml) was diluted to 25 ml using distilled H20 . 
Gluteraldehyde (4%) 
8% Aqueous gluteraldehyde was diluted to 4% using PBS. 
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2.2.2 Antibodies 
Poly clonal rabbit IgG prepared against purified (recombinant) mature tissue kallikrien (TK) 
was from Dr. M. Kemme, Technische Hochschule Darmstadt, Germany. Monoclonal IgG 
against the kinin moiety of the kininogen molecule (SBK1) was from Dr. M. Webb, 
Sandoz, UK. Polyclonal rabbit anti-human kininogen IgG (I 108) was from Dr. W. Muller-
Ester!, University of Mainz, Mainz, Germany. Polyclonal rabbit anti-human plasma 
kallikrein (PK) was also provided by Dr. W. Muller-Ester!, University of Mainz, Mainz, 
Germany. Evidence of specificity of antibodies is given by Henderson et aI, 1994. 
Polyclonal rabbit anti-human B2 receptor IgG (ED & DTL, 283) was from Dr. W. Muller-
Ester!, University of Mainz, Mainz, Germany. CY3-flourochrome labelled sheep anti-rabbit 
IgG was from Sigma, St. Louis, UK). Polyclonal rabbit anti-human Bl receptor IgG was 
from Dr. F. Hess, Merck, Rahway, New Jersey, USA). An anti-peptide polyclonal antiserum 
against 8 intra- and extracellular domains of the human Bl receptor was from Dr. W. 
Muller- Ester!, University of Mainz, Mainz, Germany (Table 1). 
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Table 1 : Description of antibodies utilised in this study 
Antibody Donor Mono- or Working Antibody Supplier 
animal polyclonal dilutions raised to of 
antibody 
Tissue rabbit poly 1:500 recombinant Dr. Kemme 
Kallikrein TK (Germany), 
(TK) Professor 
Bhoola 
kinin mouse mono 1:500 kininogen Dr. Webb 
(SBK1) molecule (Sandoz, 
USA) 
kininogen rabbit poly 1:250 kininogen Dr. Muller-
(lI08) molecule Ester! 
(Germany) 
Plasma rabbit poly 1 :250 plasma Dr. Muller-
Kallikrein kallikrein Ester! 
(PK) (Germany) 
Bl rabbit poly 1:100 Human Bl Dr. Hess 
Receptor receptor (Merck, 
peptide USA) 
loops 
Bl rabbit poly 1:100 Human Bl Dr. Muller-
Receptor receptor Ester! 
peptide (Germany) 
loops 
B2 rabbit poly 1:250 Human B2 Dr. Muller-
Receptor receptor Ester! 
peptide (Germany) 
loops 
(All reagents not otherwise stated, were of analytical grade, obtained from Sigma chemicals, 
UK). 
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2.2.2 Light microscopy 
2.2.2.1 Tissue preparation 
The isolated neutrophils from were pipetted onto a glass slide, air-dried and fixed with 
paraformaldehyde (2% in PBS, 10 min). The slides were stored at 4° C. Cells were 
immunostained using the peroxidase anti-peroxidase (PAP) method, using the universal PAP 
kit (Signet laboratories, Dedham, Massachusetts 02026, USA). Wax embedded synovial 
fluid tissue was rehydrated with xylene and a graded series of alcohol (100%, 90%, 70%) 
and thereafter immunolabelled with the appropriate antibodies. 
2.2.2.2 Immunolabelling procedure 
Following blocking of Fc sites with normal human serum, the neutrophil smears were 
sequentially incubated with the appropriate primary antibody for 18 h, a sheep anti-rabbit 
immunoglobulin linking agent (50 /.ll of the anti-species antibody (Signet laboratories, USA) 
in 0.01 M PBS, 0.1% NaN3, 1% carrier protein) for 20 min, and PAP (fig 5) (50 /.ll of 15 
ml complex in 0.01 M PBS, 1% carrier protein) for 40 min. Visualisation of the 
Immunoenzyme complex was achieved by incubation with 3-amino-9-ethyl-carbazole 




Figure 5: Visualisation of the immunoenzyme complex using the PAP marker 
The PAP ring consists of 3 molecules of horseradish peroxidase and two 
antibodies 
Figure 6: Immunocytochemical bridge by which the immunoenzyme complex enables 
visualisation of the antigen 
2.2.2.3 Counterstaining and viewing 
After immunostaining, the smears were counterstained with 2% toludine blue, mounted in 
Kaiser's jelly and viewed under a Nikon Optiphot photomicroscope. 
2.2.3 Transmission electron microscopy (TEM) 
2.2.3.1 Immunolabelling procedure 
The isolated neutrophils were washed with PBS containing sodium azide (0.2%) to prevent 
contamination in the medium. The suspended cells were pipetted into microfuge tubes and 
sequentially prefixed with paraformaldehyde (1% in PBS) for 15 min, incubated with the 
primary antibody (1 :500, v/v) for 3 h, and as a blocking step, the cells were washed with 
PBS containing bovine serum albumin (1 %, v/v) and human IgG (1 %, v/v), and spun at 300 
g for 4 min into a soft pellet. The cells were incubated with an anti-species antibody 
coupled with 10 nm gold particles (fig 7) for 2 h (Amersham International, 
Buckinghamshire, UK) and fixed overnight in glutaraldehyde (4% in PBS). 
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Figure 7: Immunolocalisation of the antigen in tissue using gold colloidal probes 
2.2.3.2 Tissue preparation 
Pellets were fixed in 4% glutaraldehyde overnight and after a washing in PBS, the pellets 
were post fixed in 1% osmium tetroxide (OS04) in 0.1 M phosphate buffer for 45 min. 
Pellets were dehydrated through a graded series of alcohol, embedded in epoxy-araldite 
resin and cured overnight at 36°C. Ultrathin sections were cut on a Reichert Ultracut 
ultramicrotome and picked up on Cu grids (200 mesh), counterstained with lead citrate and 
uranyl acetate, and viewed in a Joel 100C transmission electron microscope. 
2.2.4 Confocal microscopy 
2.2.4.1 Sample preparation 
The isolated neutrophils were pipetted on to a glass slide, air-dried and fixed with 
paraformaldehyde (4% in PBS, 1 min). The slides were stored at 4°C until immunolabelled 
and viewed in a confocal microscope (Leica, Heidelberg, Germany). 
2.2.4.2 Immunolabelling procedure 
The neutrophil smears and rehydrated wax sections were rinsed with PBS containing bovine 
serum albumin (1%, v/v) for 20 min, and sequentially incubated with the appropriate 
primary antibody (1:500) for 3 h, rinsed in PBS and incubated with fluorescein-
isothiocyanate (FITC)-conjugated F(ab)2 fragments (fig 8) of antispecies IgG (1 :250, v/v) 
for 30 min. 
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2.2.4.3 Viewing of specimens 
The specific wavelengths of the resulting emitted light beam (485 nm for FITC, 514 nm 
for CY3) within cells was detected with a confocal microscope equipped with an excitatory 
argon laser. The argon laser has spectral lines at 488 nm and 514 nm. The FITC probe has 
an optimal excitation wavelength of 485 ± 11 nm and an optimal emission wavelength of 
± 530 nm while the CY3 probe has an optimal excitation wavelength of 546 ± 5 nm and 
an optimal emission wavelength of ± 590 nm. The microcope optically collects the emitted 
fluorescent light from sequential positions in a grid format within any focal plane of the 
objective and reconstructs the reading from these points into a mosiac format, thereby 
achieving visualisation of the immunostained cell antigens throughout that plane (fig 11). 
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Figure 8: Localisation of the antigen in tissue by fluorescent microscopy 
2.2.5 Immunocytochemical controls 
The immunolocalisation controls included omission of the primary antibody or replacement 
by non-immune serum to assess the validity of the labelling method. Controls also included 
replacement of the primary antibody with the diluted, specific antibody preabsorbed with 
the respective antigen to assess the specificity of the primary antibody. Negative labelling 
results in both these controls will indicate accuracy of the method and specificity of the 
antibody. 
2.2.6 Release Experiments 
2.2.6.1 Enzymes 
TK was from Dr. M. Kemme, Technische Hochschule Darmstadt, Germany), PK, trypsin 
and bacterial proteases Nagarse and Serratiopeptidase were from Sigma, St. Louis, UK. 
2.2.6.2 Dose - response 
Mter separation of neutrophils and washing with PBS, the pellets were resuspended in PBS 
containing 5 mM/I glucose, oxygenated (95% O2 and 5% CO2 dispensed from an Mrox, 10 
I cylinder) and dispensed into microfuge tubes for dose-response measurements. One mI 
each, of a 20, 100, and 500 ng/ml enzyme concentration was added to microfuge tubes 
containing neutrophils, but for controls, neutrophils were incubated without the enzyme. 
After 20 min incubation, the cells were pelleted (10 000 x g, 5 min, room temperature), 
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spotted onto glass slides and immunolabelled with the appropriate primary antibody and 
fluorescent marker. The different dose effects on the kinin moiety contained in the 
kininogen molecule on the surface of the neutrophil were observed using a confocal 
mIcroscope. 
2.2.6.3 Time - dependence procedure 
After separation of neutrophils and washing with PBS, the pellets were resuspended in PBS 
containing 5 mM/I glucose, oxygenated (95% O2 and 5% CO2 dispensed from an Afrox, 10 
I cylinder) and dispensed into microfuge tubes for time -dependent measurements. One ml 
each of a 100 ng/ml enzyme concentration was added to microfuge tubes containing 
neutrophils but for a control, neutrophils were incubated without enzyme. At 0, 15 and 30 
min intervals, the cells were pelleted (10 000 x g, 5 min, room temperature), spotted onto 
glass slides and immunolabelled with the appropriate primary antibody and fluorescent 
marker. The effects of different times of exposure of the enzymes to the kinin moiety on 





3.1 Controls - Normal neutrophils 
3.1.1 Light microscopy 
Demonstration of the kinin forming enzymes and their substrates on the normal human 
neutrophil was achieved at fust by light microscopy immunostaining. All components of 
the kallikrein-kinin system rendered intense labelling results when incubated with the 
appropriate primary antibody. Immunoreactive tissue kallikrein (fig 9), prokallikrein (fig 
10), PK (fig 11) and kininogen (fig 12) were observed as intense red staining imparted by 
the aminoethylcarbazole (AEC) chromogen. The mono clonal antibody, (SBKl) directed 
against the bradykinin sequence in the kininogen molecule also immunoreacted intensely 
with the antigen localised on the surface of the neutrophils harvested from normal blood 
(fig 13). 
An antiserum is specific when it contains primary antibodies reacting only with the antigen 
to be localised with no cross-reactivity with other compounds. The absorption of an 
antiserum with the antigen to which it was raised represents a test for such specificity. 
Inhibition of each label was obtained when the antiserum was pre-absorbed with the 
specific antigen. A typical result is illustrated in fig 14, in which the antiserum SBKl was 
pre-absorbed with bradykinin. Replacement of the primary antibody with the pre-immune 
equivalent was done only at the beginning of each set of experiments because of the 
quantity required and the expense and availability of antibodies. In experiments that 
followed, the primary antibody was replaced with buffer only. In controls where primary 









Immunolocalisation of TK in neutrophils isolated from normal, healthy 
volunteers 
Immunolocalisation of proTK in neutrophils isolated from normal, healthy 
volunteers 
Immunolocalisation of PK in neutrophils isolated from normal, healthy 
volunteers 
Immunolocalisation of kininogen in neutrophils isolated from normal, healthy 
volunteers 






Figure 15 : 
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Immunovisualisation of the kinin moiety on the surface of the human 
neutrophil 
Antibody control showing no labelling when the antibody was preabsorbed 
with the respective specific antigen 
Antibody control showing no labelling when the antibody was replaced with 
buffer 
(Bar = 10 fl) 
3.1.2 Transmission electron microscopy 
Although labelling was achieved, a more exact localisation within the cell or on its surface 
was difficult to ascertain with light microscopy. In order to achieve a more accurate cell 
distribution profile, resin embedded cells were immunolabelled with colloidal gold for 
visualisation by electron microscopy. 
In immunocytochemistry, a compromIse must be sought between optimal labelling and 
retention of ultrastructural detail. For this reason, the suspended cells were post-fixed in 4% 
glutaraldehyde, which optimally preserves the ultrastructure without destroying antigenicity. 
Immunogold labelling for tissue kallikrein showed immunoreactive TK (fig 16) and ProTK 
(fig 17) within the cell. The kinin moiety was observed as clusters of gold deposits on the 
surface of the neutrophils isolated from blood of normal healthy volunteers (fig 18). The 
density of immunogold complexes on the cells differed between cells. Of the various cell 
types, localisation was observed only in the neutrophils. Where the primary antibody was 
replaced with buffer, no gold deposits were observed (fig 19). Kininogens, both LK and HK 
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Electron micrograph demonstrating immunoreactive TK 
Electron micrograph demonstrating immunoreactive proTK 







Electron micrograph of a neutrophil isolated from a normal, healthy volunteer 
exhibiting clusters of gold deposits on the surface 
Electron micrograph showing no gold deposits when the primary antibody 
was replaced with buffer 
(Bar = 100 nm) 
3.l.3 Confocal microscopy 
In order to create multi -dimensional, high resolution optical constructs of the 
immunolocalised components of the kinin system, on and within the neutrophil, the 
powerful imaging technique of confocal scanning laser microscopy was used (fig 20). 
Progressive scanning of the cellular field, from the surface to the deeper layers, provided 
optical images of high clarity. 
The images obtained for immunolabelled TK, proTK, PK, kininogen and kinin from blood 
of healthy volunteers are illustrated in figs 21, 22, 23, 24 and 25 respectively. Doubts have 
been expressed as to whether TK is emniocytosed from the circulation by neutrophils or is 
synthesised in situ in neutrophil stem cells. Smears prepared from the blood of patients with 
chronic myeloid leukaemia revealed intense immunostaining to TK and prokallikrein in the 
cytoplasmic granules of precursor cells of the neutrophil cell line (fig 26, 27). Myelocytes 
showed significant immunoreactivity while no labelling was observed in other precursor 
cells. Furthermore, experiments with the kinin Bl and B2 receptors indicated that there was 
no induction of the receptors in the normal neutrophils. Figure 28 shows the visualisation 
of the antigen in different optical planes. The image processing programme recorded the 
fluorescence emitted from the FITC-Iabelled F(ab)2 secondary antibody, linked to the 
specific primary antibody, with a pseudocolour gradient that ranged from white-gold 
(maximal) to brown (nil), giving an estimate of the amount of antigen present in each 
optical plane. 
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A particular advantage of a confocal microscope is its ability to do optical sectioning at 
selectible positions on the z-axis. After having determined the height of the z-axis of the 
labelled cell, the microscope was focussed halfway down the z-axis on the middle part of 
the cell. At this point the cell membrane may be visible as a ring structure around the 
cytoplasm, which eliminates the problem encountered with other microscopes, where 
labelling which may occur at the top or bottom surfaces may appear as labelling inside the 













































































Confocal microscopic images of immunolabelled TK 
Immunolabelled ProTK in the human neutrophil 













Immunolocalisation of the kininogen molecule on the neutrophil surface 










Intense labelling of TK in leukaemic blood cells 






Figure 28: Immunocytochemical localisation of kinin in different optical planes 
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3.2 Release of the kinin moiety from kininogen on the external surface of the 
neutrophil membrane 
3.2.1 Time-dependence study 
The ability of different enzymes to release the kinin molecule from kininogens located on 
the neutrophil surface was examined by incubating human neutrophils with both kinin-
releasing enzymes and bacterial proteases for different time intervals. Confocal microscopy 
was used to follow the timed release of kinins from neutrophil-bound kininogens. 
Neutrophils were incubated with the known kininogenases: TK (fig 29 a-d), PK (fig 30 a-
d), trypsin (fig 31 a-d), the bacterial proteases nagarse, and serratiopeptidase. (figs 32, 33 
a-d) for 0 (a), 15(b) and 30 min (c). The presence or absence of kinin was confrrmed by 
immunolabelling with the specific SBK1 antibody. The immunolabelling procedure 
followed FITC labelling and viewing by confocal microscopy. Cells treated with PK, TK 
and trypsin showed a considerable loss of staining which was completed by 30 min. 
However, the time-response of the bacterial proteases was considerably longer (observed 
for a further 2 h), with loss of staining only commencing at 30 min. No labelling was 







Time-dependent release of kinin after incubation with TK. 







Time-dependent release of kinin after incubation with PK. 







Time-dependent release of kinin after incubation with trypsin. 










Time-dependent release of kinin after incubation with nagarse. 




Figure 33 : Time-dependent release of kinin after incubation with serratiopeptidase. 
(a) 0, (b) 15 and (c) 30 min; method control (d) 
3.2.2 Dose-response study 
In order to determine the potency of the different doses of the various enzymes used for the 
release of kinin from the neutrophil surface, neutrophils were incubated with 20, 100 and 
500 ng/ml of the enzyme. After 20 min, the kinin antibody SBKl was used in the labelling 
procedure. It was observed that for TK and PK, an increase in the concentration of enzyme 
used resulted in a rapid drop in staining (figs 34 a-d, 35 a-d, respectively). However, with 
trypsin and the bacterial proteases, this decrease in staining was gradual (figs 36 a-d, 37 a-
d, 38 a-d). There was no labelling in the immunocytochemical controls when the antibody 










Release of kinin from the neutrophil surface after incubation of the 
neutrophils with different doses of TK. 








Release of kinin from the neutrophil surface after incubation of the 
neutrophils with different doses of PK. 







Figure 36: Release of kinin from the neutrophil surface after incubation of the 
neutrophils with different doses of trypsin. 






Figure 37: Release of kinin from the neutrophil surface after incubation of the 
neutrophils with different doses of nagarse. 








Figure 38 : Release of kinin from the neutrophil surface after incubation of the 
neutrophils with different doses of serratiopeptidase, 
(a) 20, (b) 100 and (c) 500 ng/ml; method control (d) 
3.3. Infections 
Discovery of kininogen together with the localisation of PK on domain 6 and the 
intracellular localisation of tissue kallikrein has led to the novel view that during 
degranulation of neutrophils, under conditions in which the proTK and preTK could be 
activated, could provide a mechanism for release of kinin from the surface of neutrophils. 
In sepsis, a major manifestation is hypotension, a cardinal property of kinins. Therefore, the 
question posed was, whether or not kinin could be released from neutrophils by the 
kallikreins themselves, and/or by bacterial proteases? In the first instance, therefore, the 
time- and dose- dependent experiments were designed. Once the possibility of the release 
of kinin by the kininogenases (tissue and PKs, trypsin) and bacterial proteases was 
established, experiments were undertaken to determine whether kinin could be released from 
circulating neutrophils of patients with bacterial infections. 
3.3.l. Tuberculosis meningitis and pneumonia 
In ten patients with tuberculosis meningitis, immunolabelling (with AEC for light 
microscopy) indicated a distinct loss of the kinin moiety on the neutrophil surface (fig 39 
b compared to the normal fig 39 a). A loss of the reaction product observed when 
neutrophils from 10 pneumonia patients were labelled with SBK1 (fig 40 a-normal, fig 40 
b-loss of kinin) indicated a loss of kinin from the kininogen molecule but this loss of the 
kinin molecule was not profound. There was no labelling for the antigen when the primary 









Immunolocalisation of the kinin moiety of kininogen molecule on the surface 
of neutrophils 
Neutrophils from normal healthy volunteers 
Neutrophils from patients suffering from tuberculosis meningitis 







Immunolocalisation of the kinin moiety of the kininogen molecule on the 
surface of neutrophils 
Neutrophils from healthy volunteers 
Neutrophils from patients suffering from pneumonia 







Figure 41: Control labelling for the kinin moiety of kininogen molecule on the surface 
of neutrophik 
The control consisted of omission of the primary antibody 
(Bar = 10 I!) 
The cells were subjected also to electron mlcroscopy immunolabelling procedures as 
previously described. Eight out of 10 pneumonia patients showed a distinct loss of kinin 
on the surface of the neutrophil (fig 42 a -normal, fig 42 b-Ioss of kinin) confirming the 
light microscopy results. 
As already observed with electron and light microscopy, there was a distinct loss of the 
kinin moiety on the surface of circulating neutrophils of pneumonia patients as illustrated 
by confocal microscopy (fig 43 a-normal, fig 43 b-Ioss of kinin). 
3.5. Clinical disorders 
An inflammatory response is made up of many stages, the first of which is changes in 
vascular calibre and tone and an increase in vascular permeability that results in the 
formation of protein-rich exudates. Neutrophils are attracted to the site of inflammation by 
chemotactic factors formed in the very early stage of inflammation. They initiate migration 
by causing neutrophils to margin ate and adhere to the endothelium of capillaries (Ryan et 
aI., 1977; Hess et aI., 1994). Neutrophils then form endothelial gaps and migrate into the 
interstitial tissue spaces via these gaps. The mechanism by which neutrophils form 
endothelial gaps and migrate through them is unknown. However, the immunolocalisation 
of TK, HK and LK and PK on the human neutrophil is significant, and suggests a possible 
role in the diapedesis of these cells between · capillary cells (fig 44). As a typical example 
of an inflammatory disorder, rheumatoid arthritis patients were chosen to determine whether 









Electron micrograph of the neutrophil showing kinin on the surface of 
neutrophils 
Neutrophils from normal, healthy volunteers 
N eutrophils from pneumonia patients 









Confocal microscopy images of kinin on the surface of neutrophils 
Neutrophils from normal, healthy volunteers 




Figure 44: Diapedesis of neutrophils and migration through capillary cells 
Rahman et al. (1994) reported that pain and swelling in inflammatory joint disease may be 
mediated by kinins formed by the enzymatic action of kallikreins. Furthermore, the 
hypothesis that kinins generated by the neutrophil-borne contact system might act in an 
autocrine manner is consistent with the finding that activated PK causes the release of 
elastase from neutrophils. Henderson et al. (1994) concluded that attachment to HK is a 
major requirement for the observed effect of PK on neutrophils to release kinins. The 
released kinins could regulate neutrophil function by activation of autocrine receptors . The 
question of whether or not the released kinin could affect kinin receptors on the neutrophil 
was examined by immunolocalisation of the Bz receptors on the neutrophil surface by 
confocal microscopy. It was observed that there was an increased signal for Bz receptors 
only on synovial fluid neutrophils (Fig 45), but not on those in the circulation (Fig 46). 
There appeared to be no upregulation or induction of the Bl receptor in the neutrophil 
isolated from rheumatoid arthritis patients. 
A credible aIm therefore was to determine whether kinin could be released from the 
circulating neutrophils of patients with rheumatoid arthritis. Structural detail of the 
neutrophil was demonstrated on phase contrast microscopy (fig 47). The image processing 
programme of the confocal miscroscope was used to record the fluorescence emitted from 
the FITC labelled secondary antibody linked to the primary antibody with pseudocolour 
gradients. In all of the 25 RA patients, there was a distinct loss of the kinin moiety from 
the circulating (Fig 48) and synovial fluid neutrophils (Fig 49) as compared to normal 






Figure 45: Synovial fluid neutrophils from rheumatoid arthritis patients immunolabelled 










Circulating neutrophils from rheumatoid arthritis patients immunolabelled for 
B2 receptors 









Circulating neutrophils from rheumatoid arthritis patients immunolabelled for 
immunoreactive kinin 
Synovial fluid neutrophils from rheumatoid arthritis patients immunolabelled 




In studies by Henderson et al. (1994), the Hageman factor XII-kallikrein contact-phase 
assembly was visualised on the external surface of the neutrophil cell membrane. A first 
step in the present study therefore, was to confirm these novel findings . Because of the 
binding of the HK-plasma pre-kallikrein complex on the neutrophil membrane (Henderson 
et aI. , 1992), activation of PK may result in the formation of bradykinin. The sequence of 
biochemical events of such a phenomenon involves the formation of the kinins from HK 
or LK on the surface of the neutrophil, either by the FXII-mediated activation of PK or by 
the release of TK in its active form. The spatial configuration of the contact-phase proteins 
therefore, uniquely places the neutrophil to participate in inflammatory disorders and in 
infections. 
The intracellular identification of tissue prokallikrein in neutrophils and myeloid stem cells 
strongly suggested the in situ synthesis of tissue kallikrein (TK) in granulocytes. The 
appearance of maximal labelling as a ring on the surface of the cell indicated that the kinin 
moiety is associated with the surface membrane of the cell. 
4.1. Profiles of imaging techniques to visualise tissue kallikrein and the kinin moiety on 
the external surface of the neutrophil membrane 
In immunocytochemistry one detection marker widely used is the peroxidase-anti-peroxidase 
(PAP) complex. The PAP rings consist of 3 molecules of horseradish peroxidase and two 
antibodies (fig 5). PAP will react only with the free binding site of the specific anti-
immunoglobulin in the link serum. For this reason it provides a highly specific method of 
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labelling. This is also a highly sensitive method of labelling because of the amplifying 
effect of the enzymatic activity. A few molecules of protein at a site can therefore generate 
a much larger amount of reaction product upon incubation. Results of the PAP labelling 
experiments clearly indicated that the kinin moiety of the kininogen molecule was released 
from the neutrophil surface in patients with infections. Immunogold studies were undertaken 
to confirm at the ultrastructural level, the presence or absence of the kinin moiety from the 
surface membrane of these neutrophils. 
In addition to the initial light microscopy experiments with AEC marker that illustrated a 
release of the kinin molecule from kininogen, using electron and confocal methods of 
labelling and visualisation, it was also observed that there was a loss of the kinin moiety 
from the kininogen on the external surface of neutrophils harvested from patients with 
infections. 
With a laser scanning confocal microscope it is possible for emitted light from one very 
small area only to be detected, by allowing the light to pass through a very small aperture. 
Therefore, no scattered light from other planes of the tissue that may obscure the final 
image, is detected. A representative image of any focal plane is obtained by scanning, or 
combining recording data from illuminated areas in a grid format. Optical sectioning is 
possible by viewing consecutive focal planes of the specimen. Therefore, the need for 
physical sectioning of a specimen is eliminated. 
The advantage of this method of visualisation is that it is also possible to view live cells 
and furthermore, a transmitted light source and detector makes phase contrast visualisation 
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possible. A phase contrast image may be obtained from an unstained specimen. With two 
channels available, separate images of double labelled samples may be obtained. Images 
may be stored on the hard drive, stiffies or on a WORM (write once read many) drive. It 
is also possible, for record purposes, to photograph images off a flat, non-reflective screen. 
Specific advantages of the software package are that magnification bars calculated by the 
computer, as well as an intensity bar, indicating the intensity of fluorescence, may be added 
to the recorded image. Morphometric analysis, as well as 3D reconstruction of a thick 
specimen, are just two of the complex calculations feasible. A definite advantage is the 
ability to obtain a vertically scanned image from a specimen. This mode of imaging will 
allow the observation of the interaction between bacteria and cells in tissue culture. 
The confocal images of fixed, permeabilised neutrophils provided multi-dimensional 
constructs of the neutrophil, and the intensity of fluorescence reflected the relative amounts 
of the kinin molecule detected on neutrophils harvested from both healthy blood as well as 
from disease states. 
4.2. Release of kinin 
The coupling of kininogen to appropriate receptors on the surface of the neutrophil may 
serve several functions, viz: (1) surface bound kininogens on platelets, together with 
prekallikrein and factor XI could locally trigger the endogenous coagulation cascade (fig 
50), or (2) in the case of neutrophils, proteolytic processing of surface bound LK and HK 
by the kallikreins could form kinins. The locally released kinin may enhance the passage 
of the neutrophils into the extracellular space by causing the endothelial cells to retract and , 
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thereby opening the junctions between the cells (Gabbiani et aI., 1970; Oyvin et aI., 1970; 
Majno et aI., 1972). This mechanism would promote the transudation of plasma constituents 
by controlling vascular permeability, and also the passage of circulating neutrophils 
(diapedesis) into the interstitial tissue space surrounding the site of injury or inflammation 
(Wright et aI., 1979). 
4.3. Role in infections and sepsis 
It was observed that the inflammatory response to a number of stimuli, including infection, 
severe trauma, and burns appears to be similar, independent of the initiating cause. This 
response is characterised by fever, rapid heart rate, rapid respiratory rate and leucocytosis. 
In more serious forms, these signs and symptoms may progress to hypotension, shock, 
organ dysfunction and/or failure and death. This state has been defined as sepsis and in the 
more severe states as septic shock, when associated with infection. Loss in the amount of 
the kinin moiety residing in the kininogen molecules on the surface of the neutrophil has 
been demonstrated in sepsis patients, and therefore, may be a manifestation of sepsis 
(Naidoo et ai., 1994b). This in vitro study on infectious states supports the view that 
circulating bacterial proteases, either directly or by complex cascade mechanisms, may 
release kinins from the surface of neutrophils - a finding of considerable clinical 
importance. Patients presenting with pneumonia also showed a distinct loss of the kinin 




Figure 50: Contact phase assembly on the surface of the neutrophil cell membrane 
4.4. Neutrophil chemotaxis and role in inflammatory disorders 
Complex mechanisms, which come into play at the receptors on the cell surface, control 
cellular interactions and these include adhesion molecules, selectins, integrins and the 
superfamily of G-proteins. Furthermore, the soluble cell mediators, cytokines, and 
components of the extracellular matrix, such as collagen also play a pivotal role in cellular 
interactions. Disturbance of anyone of these systems may evoke pathological disorders. In 
the development of inflammation, adhesion molecules play an essential role in the 
movement of cells to the inflammatory sites. After they have marginated, the activated cells 
migrate by diapedesis towards the site of inflammation, by following of chemotactic signals. 
The adhesion between the cells, alone, is insufficient to induce their migration. The 
adherence phenomena depend on a process that is strictly controlled by cytokines and 
enable the intervention of cell-cell reactions and cell-protein recognition of the extra-cellular 
matrix. Cytokines play a key role in the control of the expression and avidity of membrane 
receptors for ligands. 
The most important chemotactic factors which attract neutrophils and cause them to 
marginate along the endothelium of capillaries are complement C5a and interleukin-1 (IL 1). 
Thereafter, the neutrophils undergo diapedesis through the endothelial cell gaps. In vivo 
studies suggest that the endothelial cells undergo certain changes during injury and make 
themselves "sticki l for the circulating neutrophils which are the most mobile inflammatory 
cells. Regulation by IL-2 and tumour necrosis factor (TNF) of the de novo synthesis of 
adhesion molecules showed an association with the adhesion process in experiments with 
human umbilical vein endothelial cells (Henderson et aI., 1994; Melmon et aI., 1967; 
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Kaplan et aI., 1989). 
The significance and functional importance of the components of the kinin system in 
inflammatory disorders continues to unfold with molecular mapping, and by advances in 
the geneology, gene characterisation and cloning of the kinin receptors. A powerful tool for 
elucidating the physiopathological actions of kinins has been established by the discovery 
of specific, competitive antagonists of kinin receptors. The clinical manifestations of 
systemic inflammatory response syndromes associated with infection, severe trauma, burns 
and pancreatitis appear to be similar, and attributable, at least in part to kinins. 
Though much knowledge has accumulated on the contact phase activation process, the 
nature of the physiological contact surface has remained elusive. Henderson and colleagues 
(1994) suggested a novel mechanism for the formation of kinins from kininogens on the 
surface of neutrophils . They suggested that kinins are formed on the surface of the 
neutrophil either by the activation of PPK (causing the release of bradykinin from HK by 
activated PPK), and/or the release of active TK. It was also proposed that released kinin 
initiates margination, orientates and evokes the passage of the neutrophil into the 
extracellular space by causing the endothelial cells to retract (Henderson et aI., 1994). 
Fluid accumulation in the joints of patients with rheumatoid arthritis, an immune driven 
disorder involving the release of cytokines and the activation of Band T lymphocytes, 
resembles that of inflamed tissue. Enzyme systems identified in synovial fluids include 
plasma transudates and degranulating neutrophils, and cellular damage occurs from the 
enzymatic properties of the kallikreins. Many neutrophils invade rheumatoid synovial 
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vessels, migrate to the luminal surface of the synovial membrane and accumulate in large 
numbers in the synovial fluid (Dularey et aI., 1990). Therefore, TK probably reaches the 
synovial fluid from both neutrophils and plasma exudates. Secretion from even a small 
number -of neutrophils in rheumatoid arthritis synovial fluid could result in the activation 
of the enzyme and the subsequent formation of kinins during episodes of acute 
inflammation within the joints. 
Most of the PK in synovial fluid exists as a pro enzyme complexed to HK. Conversion of 
plasma prekallikrein to its active form may be triggered through activation of HK by tissue 
matrix components such as proteoglycans, urate crystals or pyrophosphates (Cassim et aI., 
1995). PK is also believed to cause significant conversion oflatent collagenase to its active 
form in vitro (Dularey et aI., 1990) and this could be an important property of PK in the 
joint space. This activated collagenase could be responsible for the extensive cartilage and 
bone destruction seen in patients with rheumatoid arthritis, in which neutrophils invade the 
synovium and migrate in large numbers to the synovial fluid. In particular, the synovial 
membrane and the joint space are infiltrated with numerous neutrophils, which carry in and 
on their surface the kinin and fibrin generating proteolytic enzymes and cascade proteins 
(Kaplan et aI., 1989). 
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4.5. Kinin receptors and nitric oxide formation 
Most of the well characterised functional actions of kinins appear to be mediated by 
activation of the B2 receptor. Ongoing studies on neutrophils isolated from whole blood of 
patients with rheumatoid arthritis as well as from synovial fluid indicate that the density of 
the B2 receptor is increased on neutrophils isolated from the circulation while neutrophils 
isolated from synovial fluid show a loss of the B2 receptor (Cassim et aI., 1995). However, 
there appears to be no change in the regulation of the Bl receptors on neutrophils isolated 
from patients with different disease states, compared to those from normal, healthy 
volunteers. 
Kinin receptors have a seven transmembrane loop configuration and are linked to G-
proteins. One signal transduction event that kinins generate is the formation of nitric oxide. 
An important source of nitric oxide could be the C terminal arginine which is released 
following the conversion of bradykinin or kallidin into the appropriate des Arg9 kinin 
molecule (fig 51). Nitric oxide (NO), is a unique biological mediator that has been 
implicated in a variety of physiological and pathophysiological conditions (Rodeberg et aI., 
1995). It has been found to be an important regulator of vascular tone and may be the 
mediator of the hemodynamic changes in sepsis. 
Since the only physiological nitrogen donor for NO synthesis is arginine, metabolism of 
this amino acid may play a role in the regulation of NO synthesis during sepsis. Regardless 
of its origin, endogenous NO is produced through the conversion of L-arginine to L-
citrulline by NO synthase (NOS) (Berdeaux, 1993). Several isoforms of the enzyme have 
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been isolated, purified and cloned. NOS-type 1 (isolated from brain) and type III (isolated 
from endothelial cells) are termed "constitutive NOS" and produce minute amounts of NO 
which elicits physiological responses. NOS-types 11 and IV are the "inducible NOS" since 
their activation is only promoted under physiological conditions where macrophages exert 
cytotoxic effects in response to cytokines. Unlike NOS-types I and Ill, activation of NOS-
type 11 in these cells induces the formation of sufficiently large amounts of NO which act 
as a defence mechanism of the immune system. Recent studies have identified the induction 
of NO synthesis in many cell types as part of the host response to sepsis and inflammation 
(Morris and Billiar, 1994), with both detrimental and beneficial effects that depend on 
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4.6 Conclusions 
4.6.1 This study supports the hypothesis that all of the essential molecular components of 
the kallikrein-kinin system may be located in or on the surface of the neutrophil. 
4.6.2 The time-dependence and dose-response kinin release experiments indicate that the 
kinin moiety on the neutrophil surface is readily accessible for the enzymatic action 
of kallikreins, and a major loss of kinin apparently occurs upon exposure of the cells 
to active kallikreins and bacterial proteases. 
4.6.3 Experiments demonstrated an apparent loss of the kinin moiety from the 
kininogens · bound to the external surface of neutrophils in infections and 
inflammatory disorders such as rheumatoid arthritis. 
4.6.4 There appears to be no induction of the Bl and Bz receptors in neutrophils 
isolated from normal, healthy blood or blood from patients suffering from 
rheumatoid arthritis. However, there is an upregulation of kinin Bz receptors in 
neutrophils from synovial fluid isolated from rheumatoid arthritis patients. 
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4. 7 Future experiments 
4.7.1 A question that arises from this study is how the novel finding of a loss of the 
neutrophil kinin moiety can be used to investigate new strategies for the treatment 
in infectious states. With the development of appropriate kininogenase and kinin 
peptide antagonists, this prove useful in drug therapy. 
4.7.2 Since most of the functions of kinins appears to be mediated by the action of kinin 
receptors, future experiments are necessary to determine the conditions under which 
there is upregulation or downregulation of these receptors. Experiments involving 
the induction of the neutrophil Br receptor in sepsis would be significant to this end. 
4.7.3 Another important direction is comparative analysis of the signal transduction system 
regulated by the activation of the Br and B2 kinin receptors. 
4.7.4 The role of NO in neutrophil adhesion should be investigated to elucidate 
whether NO regulates neutrophil-endothelial cell interactions, and hence the 
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Pharmacology reference number 
Diagnosis 
Date of sample collection 
For all patients, circulating neutrophils were isolated for immunocytochemistry. 
Synovial fluid was also isolated from rheumatoid arthritis patients. 
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Appendix 2 
Profiles of tuberculosis meningitis patients 
Patients Age Sex Reference Date of 
no. blood 
collection 
1 42 M P22 13/07/93 
2 38 M P27 15/07/93 
3 45 M P28 15/07/93 
4 35 M P35 22/07/93 
5 40 M P52 03/08/93 
6 49 F P70 19/01194 
7 42 M P73 10/01194 
8 40 M P99 09/02/94 
9 30 M P130 25/10/94 
10 34 M P135 21111194 
11 44 M P136 21111194 
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Appendix 3 
Profiles of pneumonia patients 




1 45 M P120 05/10/94 
2 21 M P121 05/10/94 
3 35 M P122 05/10/94 
4 42 M P125 05/10/94 
5 32 M P126 15/10/94 
6 26 M P127 15/10/94 
7 30 F P128 19/10/94 
8 29 M P129 19/10/94 
9 40 M P137 22/10/94 
10 47 F P138 22110194 
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Appendix 4 
Profiles of myeloid leukaemia patients 
Patients Age Sex Reference Date of 
no. blood 
collection 
1 60 M P183 28/06/95 
2 18 M P184 28/06/95 
3 12 M P185 28/06/95 
4 14 M P186 27/06/95 
5 60 M P188 03/07/95 
6 43 F P201 11110/95 
7 38 M P202 11/10/95 
8 47 M P203 11110/95 
9 58 M P204 11110/95 
10 50 M P231 26/01196 
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Appendix 5 
Profiles of rheumatoid athritis patients 
Patients Age Sex Reference Date of 
no. sample 
collection 
1 40 F P134 18/11/94 
2 28 M P124 05/10/94 
3 64 F P154 02/03/95 
4 69 M P156 09/03/95 
5 45 F P157 09/03/95 
6 61 F P158 09/03/95 
7 31 F P160 16/03/95 
8 50 F P159 16/03/95 
9 60 F P161 16/03/95 
10 49 M P162 16/03/95 
11 61 F P164 23/03/95 
12 50 F P165 23/03/95 
13 47 F P166 23/03/95 
14 62 F P167 23/03/95 
15 39 F P169 30/03/95 
16 34 F P170 30/03/95 
17 55 F P172 06/04/95 
18 37 F P173 06/04/95 
19 54 F P174 06/04/95 
20 54 F P178 20/04/95 
21 52 F P179 20/04/95 
22 24 F P180 20/04/95 
23 50 F P181 16/05/95 
24 48 F P149 23/02/95 
25 47 F P150 23/02/95 
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